{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 464378419
| IUPAC_name = ''N'',''N''-diethyl-''N'''-[(3''S'',4a''S'',10a''R'')-6-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[''g'']quinolin-3-yl]sulfamide
| image = Quinagolide.png

<!--Clinical data-->
| tradename = Norprolac
| Drugs.com = {{drugs.com|international|quinagolide}}
| pregnancy_category =  
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 87056-78-8
| ATC_prefix = G02
| ATC_suffix = CB04
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H33N3O3S/c1-4-10-22-14-17(21-27(25,26)23(5-2)6-3)11-16-12-18-15(13-19(16)22)8-7-9-20(18)24/h7-9,16-17,19,21,24H,4-6,10-14H2,1-3H3/t16-,17+,19-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = GDFGTRDCCWFXTG-ZIFCJYIRSA-N
| PubChem = 55645
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2343034
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 80Q9QWN15M
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07217
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 290962

<!--Chemical data-->
| C=20 | H=33 | N=3 | O=3 | S=1 
| molecular_weight = 395.56 g/mol
}}

'''Quinagolide''' ([[International Nonproprietary Name|INN]], [[British Approved Name|BAN]]) (brand name '''Norprolac''') is a [[binding selectivity|selective]] [[D2 receptor|D<sub>2</sub> receptor]] [[agonist]] that is used to reduce elevated levels of [[prolactin]] ([[hyperprolactinemia]]).<ref>{{cite journal |title = The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas |author1=Antonella Di Sarno |author2=Maria Luisa Landi |author3=Paolo Marzullo |author4=Carolina Di Somma |author5=Rosario Pivonello |author6=Gaetana Cerbone |author7=Gaetano Lombardi |author8=Annamaria Colao |journal = Clinical Endocrinology |volume = 53 |issue = 1 |pages = 53–60 |date=July 2000 |doi = 10.1046/j.1365-2265.2000.01016.x |url = http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2265.2000.01016.x/full |pmid=10931080}}</ref> It has also been found to be effective in the treatment of [[breast pain]].<ref name="Pluchinotta2015">{{cite book|author=Alfonso M Pluchinotta|title=The Outpatient Breast Clinic: Aiming at Best Practice|url=https://books.google.com/books?id=m5twCAAAQBAJ&pg=PA167|date=20 April 2015|publisher=Springer|isbn=978-3-319-15907-2|pages=167–}}</ref>

==See also==
* [[Bromocriptine]]
* [[Cabergoline]]
* [[Lisuride]]
* [[Pergolide]]
* [[Terguride]]

==References==
{{Reflist|2}}


{{Dopaminergics}}

[[Category:Benzoquinolines]]
[[Category:D2-receptor agonists]]
[[Category:Phenols]]
[[Category:Tocolytics]]


{{drug-stub}}